Halozyme picks a new CFO; Retrophin gets on the FDA fast track;

@FierceBiotech: FDA says Sanofi and Regeneron's cardio contender looks approvable. But for whom? More | Follow @FierceBiotech

@JohnCFierce: ICYMI: Vertex beefs up its cystic fibrosis pipeline with $1.2B Parion R&D pact. Article | Follow @JohnCFierce

@DamianFierce: Next week's PCSK9 adcomms are at the "Hilton Washington DC/Gaithersburg," which is like saying "Marriott U.S./Greenland." | Follow @DamianFierce

> Halozyme ($HALO) CFO David Ramsey is retiring later this summer, to be replaced by former Shire ($SHGP) and Amgen ($AMGN) executive Laurie Stelzer. News

> Retrophin ($RTRX) picked up the FDA's fast-track designation for RE-024, a drug in development for the rare pantothenate kinase-associated neurodegeneration, or PKAN. With the nod, the agency promises to cut months off of RE-024 review time once it's submitted. More

Medical Device News

@FierceMedDev: Exact Sciences joins forces with MD Anderson for lung cancer Dx development. More from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: Journalists who were jailed by the feds call for federal shield law | National Press Club. More | Follow @VarunSaxena2

@EmilyWFierce: OPKO scoops up Bio-Reference Laboratories for $1.47B. News | Follow @EmilyWFierce

> China's Mindray Medical weighing offer from management to take company private. Story

> Medtronic aims for diabetic consumer tech in deals with Samsung, Glooko and connected MiniMed clearance. Article

Pharma News

@FiercePharma: FDA launches safety investigation of controversial raw foods for pets. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: FDA warning letter says Czech company shipped bacteria contaminated APIs to the U.S. More | Follow @EricPFierce

@CarlyHFierce: AbbVie, J&J gallop toward first-line Imbruvica sales with new survival data. FiercePharma report | Follow @CarlyHFierce

> AstraZeneca takes its emerging markets push to Algeria with $125M expansion. Story

> NICE sings a different tune for Bayer's prostate cancer drug Xofigo. Report

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.